Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients (2020)
Source: Basic Clinical Pharmacology & Toxicology. Unidades: FCFRP, FMRP
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA, RECEPTORES DE DROGA, ESTRÓGENOS
ABNT
XIMENEZ, João Paulo Bianchi et al. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients. Basic Clinical Pharmacology & Toxicology, v. 126, n. 5, p. 432-436, 2020Tradução . . Disponível em: https://doi.org/10.1111/bcpt.13368. Acesso em: 04 out. 2024.APA
Ximenez, J. P. B., Lanchote, V. L., Bello, M. A., Iocken, F. H. S., Obadia, R. C. M., Sousa, V. P. de, & Suarez-Kurtz, G. (2020). Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients. Basic Clinical Pharmacology & Toxicology, 126( 5), 432-436. doi:10.1111/bcpt.13368NLM
Ximenez JPB, Lanchote VL, Bello MA, Iocken FHS, Obadia RCM, Sousa VP de, Suarez-Kurtz G. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients [Internet]. Basic Clinical Pharmacology & Toxicology. 2020 ; 126( 5): 432-436.[citado 2024 out. 04 ] Available from: https://doi.org/10.1111/bcpt.13368Vancouver
Ximenez JPB, Lanchote VL, Bello MA, Iocken FHS, Obadia RCM, Sousa VP de, Suarez-Kurtz G. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients [Internet]. Basic Clinical Pharmacology & Toxicology. 2020 ; 126( 5): 432-436.[citado 2024 out. 04 ] Available from: https://doi.org/10.1111/bcpt.13368